Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 45 | 2024 | 357 | 10.180 |
Why?
|
Autonomic Nervous System | 9 | 2021 | 65 | 3.830 |
Why?
|
Heart Atria | 19 | 2024 | 281 | 3.590 |
Why?
|
Catheter Ablation | 18 | 2024 | 253 | 3.260 |
Why?
|
Atrial Remodeling | 5 | 2024 | 24 | 3.170 |
Why?
|
Pulmonary Veins | 13 | 2023 | 93 | 2.650 |
Why?
|
Myocytes, Cardiac | 13 | 2024 | 314 | 2.320 |
Why?
|
Genetic Therapy | 6 | 2021 | 370 | 2.150 |
Why?
|
Dogs | 21 | 2024 | 704 | 1.920 |
Why?
|
Cryosurgery | 11 | 2023 | 54 | 1.850 |
Why?
|
Heart | 7 | 2019 | 574 | 1.790 |
Why?
|
Electrophysiologic Techniques, Cardiac | 7 | 2024 | 53 | 1.370 |
Why?
|
Vagus Nerve | 5 | 2011 | 49 | 1.110 |
Why?
|
Heart Failure | 7 | 2021 | 1188 | 1.000 |
Why?
|
Arrhythmias, Cardiac | 7 | 2024 | 200 | 0.960 |
Why?
|
Parasympathetic Nervous System | 4 | 2019 | 36 | 0.940 |
Why?
|
Calcium Signaling | 8 | 2021 | 138 | 0.910 |
Why?
|
Heart Rate | 10 | 2024 | 498 | 0.850 |
Why?
|
Atrial Appendage | 3 | 2019 | 33 | 0.840 |
Why?
|
NADPH Oxidase 2 | 1 | 2020 | 22 | 0.720 |
Why?
|
Nerve Growth Factor | 1 | 2019 | 18 | 0.690 |
Why?
|
Nervous System Diseases | 1 | 2021 | 163 | 0.680 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2018 | 23 | 0.680 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2020 | 217 | 0.650 |
Why?
|
Action Potentials | 8 | 2024 | 600 | 0.640 |
Why?
|
Animals | 29 | 2024 | 27419 | 0.630 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 557 | 0.620 |
Why?
|
Excitation Contraction Coupling | 3 | 2017 | 8 | 0.620 |
Why?
|
Sympathetic Nervous System | 3 | 2019 | 96 | 0.600 |
Why?
|
Defibrillators, Implantable | 5 | 2023 | 145 | 0.590 |
Why?
|
Fibrosis | 5 | 2024 | 234 | 0.590 |
Why?
|
Electricity | 1 | 2017 | 24 | 0.580 |
Why?
|
Heart Conduction System | 2 | 2014 | 112 | 0.570 |
Why?
|
Radiopharmaceuticals | 2 | 2024 | 196 | 0.570 |
Why?
|
Atrial Flutter | 3 | 2024 | 36 | 0.550 |
Why?
|
Atrial Function | 2 | 2016 | 19 | 0.550 |
Why?
|
Pericardium | 2 | 2014 | 70 | 0.540 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2016 | 45 | 0.540 |
Why?
|
Stroke | 4 | 2021 | 987 | 0.520 |
Why?
|
Peptides | 3 | 2024 | 648 | 0.520 |
Why?
|
Oxidative Stress | 1 | 2018 | 458 | 0.510 |
Why?
|
Disease Models, Animal | 10 | 2024 | 2376 | 0.490 |
Why?
|
Adipose Tissue | 2 | 2014 | 259 | 0.490 |
Why?
|
Myocardial Ischemia | 1 | 2016 | 162 | 0.480 |
Why?
|
Carbachol | 2 | 2011 | 36 | 0.480 |
Why?
|
Sotalol | 2 | 2024 | 3 | 0.460 |
Why?
|
Electrocardiography | 7 | 2019 | 497 | 0.450 |
Why?
|
Potassium Channels | 1 | 2016 | 343 | 0.450 |
Why?
|
Body Surface Potential Mapping | 2 | 2011 | 25 | 0.450 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2012 | 16 | 0.440 |
Why?
|
Pacemaker, Artificial | 3 | 2023 | 96 | 0.420 |
Why?
|
Atrial Function, Left | 4 | 2012 | 50 | 0.410 |
Why?
|
Myocardial Contraction | 4 | 2024 | 252 | 0.400 |
Why?
|
Anti-Arrhythmia Agents | 5 | 2024 | 65 | 0.390 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2011 | 4 | 0.390 |
Why?
|
3-Iodobenzylguanidine | 1 | 2011 | 20 | 0.390 |
Why?
|
Receptor, Muscarinic M2 | 2 | 2009 | 13 | 0.390 |
Why?
|
Sarcomeres | 2 | 2024 | 27 | 0.370 |
Why?
|
Humans | 41 | 2024 | 89572 | 0.370 |
Why?
|
Atrioventricular Node | 1 | 2010 | 35 | 0.350 |
Why?
|
Autonomic Nervous System Diseases | 2 | 2021 | 22 | 0.350 |
Why?
|
Parasympathectomy | 1 | 2009 | 2 | 0.340 |
Why?
|
Cardiovascular Agents | 1 | 2009 | 54 | 0.320 |
Why?
|
Calcium | 4 | 2021 | 1175 | 0.320 |
Why?
|
Cardiac Pacing, Artificial | 6 | 2021 | 98 | 0.310 |
Why?
|
Electric Countershock | 3 | 2023 | 55 | 0.310 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 1728 | 0.310 |
Why?
|
Recurrence | 9 | 2024 | 1144 | 0.300 |
Why?
|
Anesthesia, General | 2 | 2020 | 115 | 0.300 |
Why?
|
Feasibility Studies | 3 | 2024 | 783 | 0.290 |
Why?
|
Male | 30 | 2024 | 42514 | 0.270 |
Why?
|
DNA | 1 | 2011 | 1309 | 0.250 |
Why?
|
Time Factors | 10 | 2024 | 5344 | 0.240 |
Why?
|
Microscopy, Confocal | 3 | 2016 | 278 | 0.230 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 94 | 0.230 |
Why?
|
Proteolysis | 1 | 2024 | 111 | 0.230 |
Why?
|
Female | 25 | 2024 | 46328 | 0.220 |
Why?
|
Middle Aged | 21 | 2024 | 26044 | 0.220 |
Why?
|
Long QT Syndrome | 1 | 2023 | 36 | 0.210 |
Why?
|
Autonomic Denervation | 2 | 2012 | 2 | 0.210 |
Why?
|
Retrospective Studies | 13 | 2024 | 9080 | 0.210 |
Why?
|
Myocardium | 3 | 2024 | 572 | 0.210 |
Why?
|
Rats, Sprague-Dawley | 2 | 2024 | 1237 | 0.210 |
Why?
|
Genetic Vectors | 2 | 2016 | 446 | 0.210 |
Why?
|
Postoperative Complications | 3 | 2019 | 2284 | 0.200 |
Why?
|
Aged | 16 | 2024 | 19217 | 0.200 |
Why?
|
Muscarinic Antagonists | 3 | 2012 | 58 | 0.200 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2021 | 15 | 0.190 |
Why?
|
Treatment Outcome | 11 | 2024 | 8266 | 0.190 |
Why?
|
Cardiac Electrophysiology | 2 | 2021 | 7 | 0.180 |
Why?
|
Risk Factors | 9 | 2024 | 5505 | 0.180 |
Why?
|
Myocardial Infarction | 1 | 2024 | 374 | 0.180 |
Why?
|
Ryanodine Receptor Calcium Release Channel | 2 | 2018 | 25 | 0.180 |
Why?
|
Cholinergic Agonists | 2 | 2011 | 11 | 0.180 |
Why?
|
Sodium-Calcium Exchanger | 1 | 2020 | 22 | 0.180 |
Why?
|
Renin-Angiotensin System | 1 | 2021 | 81 | 0.180 |
Why?
|
Conscious Sedation | 2 | 2020 | 68 | 0.180 |
Why?
|
Epigenomics | 1 | 2021 | 103 | 0.170 |
Why?
|
Dihydropyridines | 1 | 2019 | 7 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 3 | 2024 | 3454 | 0.170 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 121 | 0.170 |
Why?
|
Infarction | 1 | 2019 | 27 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 105 | 0.160 |
Why?
|
Heart Diseases | 2 | 2019 | 298 | 0.160 |
Why?
|
Tachycardia, Atrioventricular Nodal Reentry | 2 | 2011 | 23 | 0.160 |
Why?
|
Tachycardia | 1 | 2019 | 37 | 0.160 |
Why?
|
Research Design | 2 | 2016 | 601 | 0.160 |
Why?
|
NAV1.5 Voltage-Gated Sodium Channel | 1 | 2018 | 32 | 0.160 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 192 | 0.160 |
Why?
|
p21-Activated Kinases | 1 | 2018 | 16 | 0.150 |
Why?
|
Heart Ventricles | 3 | 2018 | 779 | 0.150 |
Why?
|
Models, Animal | 1 | 2018 | 276 | 0.150 |
Why?
|
Cryotherapy | 1 | 2016 | 30 | 0.140 |
Why?
|
Smad Proteins | 1 | 2016 | 43 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 71 | 0.130 |
Why?
|
3T3 Cells | 1 | 2016 | 97 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 77 | 0.130 |
Why?
|
Hypertension | 2 | 2013 | 746 | 0.130 |
Why?
|
Models, Theoretical | 1 | 2018 | 492 | 0.130 |
Why?
|
Intraoperative Complications | 1 | 2017 | 184 | 0.130 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 490 | 0.120 |
Why?
|
Muscular Diseases | 1 | 2015 | 64 | 0.120 |
Why?
|
Anticoagulants | 1 | 2018 | 428 | 0.120 |
Why?
|
Biomedical Research | 1 | 2019 | 400 | 0.120 |
Why?
|
Sarcoplasmic Reticulum | 2 | 2010 | 25 | 0.110 |
Why?
|
Mice | 3 | 2018 | 11787 | 0.110 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 52 | 0.110 |
Why?
|
Sarcolemma | 1 | 2013 | 31 | 0.110 |
Why?
|
Refractory Period, Electrophysiological | 2 | 2012 | 6 | 0.110 |
Why?
|
Parasympatholytics | 1 | 2012 | 19 | 0.100 |
Why?
|
Adrenergic Antagonists | 1 | 2012 | 3 | 0.100 |
Why?
|
Adrenergic alpha-1 Receptor Agonists | 1 | 2012 | 4 | 0.100 |
Why?
|
Radiography | 1 | 2014 | 809 | 0.100 |
Why?
|
Baroreflex | 1 | 2012 | 8 | 0.100 |
Why?
|
Phenylephrine | 1 | 2012 | 36 | 0.100 |
Why?
|
Prosthesis Failure | 1 | 2012 | 116 | 0.100 |
Why?
|
Obesity | 1 | 2018 | 971 | 0.100 |
Why?
|
Radionuclide Imaging | 1 | 2011 | 221 | 0.090 |
Why?
|
Adult | 4 | 2023 | 26676 | 0.090 |
Why?
|
Length of Stay | 2 | 2024 | 740 | 0.090 |
Why?
|
Administration, Oral | 2 | 2024 | 682 | 0.090 |
Why?
|
GTP-Binding Protein gamma Subunits | 1 | 2009 | 5 | 0.080 |
Why?
|
GTP-Binding Protein beta Subunits | 1 | 2009 | 6 | 0.080 |
Why?
|
Rats | 4 | 2024 | 4043 | 0.080 |
Why?
|
Cats | 1 | 2009 | 305 | 0.080 |
Why?
|
Ventricular Function, Left | 2 | 2024 | 607 | 0.080 |
Why?
|
Cyclic AMP | 1 | 2009 | 275 | 0.080 |
Why?
|
Potassium | 1 | 2009 | 255 | 0.080 |
Why?
|
Tropicamide | 1 | 2007 | 1 | 0.080 |
Why?
|
Ganglia, Autonomic | 1 | 2007 | 6 | 0.080 |
Why?
|
Vena Cava, Superior | 1 | 2007 | 60 | 0.070 |
Why?
|
Gene Expression | 1 | 2011 | 1310 | 0.070 |
Why?
|
Echocardiography | 2 | 2023 | 938 | 0.070 |
Why?
|
Electric Stimulation | 1 | 2007 | 361 | 0.070 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2007 | 201 | 0.070 |
Why?
|
Prevalence | 3 | 2016 | 1245 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2015 | 6828 | 0.070 |
Why?
|
Cardiac Catheters | 1 | 2024 | 13 | 0.060 |
Why?
|
Organotechnetium Compounds | 1 | 2024 | 11 | 0.060 |
Why?
|
Bacteriocins | 1 | 2024 | 12 | 0.060 |
Why?
|
Administration, Intravenous | 1 | 2024 | 57 | 0.060 |
Why?
|
Patient Safety | 2 | 2016 | 217 | 0.060 |
Why?
|
Calpain | 1 | 2024 | 113 | 0.060 |
Why?
|
Electric Impedance | 1 | 2023 | 110 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2024 | 435 | 0.050 |
Why?
|
Tachycardia, Ventricular | 1 | 2024 | 124 | 0.050 |
Why?
|
Rats, Inbred SHR | 2 | 2013 | 33 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 260 | 0.050 |
Why?
|
Prospective Studies | 2 | 2022 | 4309 | 0.050 |
Why?
|
Temperature | 1 | 2022 | 406 | 0.050 |
Why?
|
Catheters | 1 | 2021 | 76 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 1597 | 0.050 |
Why?
|
Ventricular Pressure | 1 | 2021 | 38 | 0.050 |
Why?
|
Ultrasonography, Interventional | 1 | 2021 | 124 | 0.050 |
Why?
|
Endothelial Cells | 1 | 2024 | 460 | 0.050 |
Why?
|
Diastole | 1 | 2020 | 141 | 0.040 |
Why?
|
Ventricular Function, Right | 1 | 2021 | 146 | 0.040 |
Why?
|
Models, Cardiovascular | 1 | 2020 | 107 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 3669 | 0.040 |
Why?
|
Weight Loss | 1 | 2021 | 228 | 0.040 |
Why?
|
Blood Pressure | 2 | 2013 | 901 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 1436 | 0.040 |
Why?
|
Electrophysiological Phenomena | 1 | 2018 | 51 | 0.040 |
Why?
|
Sus scrofa | 1 | 2017 | 51 | 0.040 |
Why?
|
Ischemic Attack, Transient | 1 | 2019 | 182 | 0.040 |
Why?
|
Reoperation | 1 | 2020 | 602 | 0.040 |
Why?
|
Contraindications, Procedure | 1 | 2016 | 7 | 0.040 |
Why?
|
Equipment Safety | 1 | 2016 | 33 | 0.030 |
Why?
|
Fluoroscopy | 1 | 2017 | 123 | 0.030 |
Why?
|
Thoracic Vertebrae | 1 | 2016 | 51 | 0.030 |
Why?
|
Spinal Diseases | 1 | 2016 | 44 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2016 | 76 | 0.030 |
Why?
|
Prognosis | 2 | 2017 | 3792 | 0.030 |
Why?
|
Monitoring, Intraoperative | 1 | 2017 | 106 | 0.030 |
Why?
|
Operative Time | 1 | 2016 | 143 | 0.030 |
Why?
|
Databases, Factual | 1 | 2020 | 857 | 0.030 |
Why?
|
Cervical Vertebrae | 1 | 2016 | 83 | 0.030 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2019 | 216 | 0.030 |
Why?
|
Echocardiography, Transesophageal | 1 | 2018 | 344 | 0.030 |
Why?
|
Computer Simulation | 1 | 2020 | 1100 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 2016 | 151 | 0.030 |
Why?
|
Recovery of Function | 1 | 2017 | 293 | 0.030 |
Why?
|
Bronchoscopy | 1 | 2017 | 162 | 0.030 |
Why?
|
Illinois | 1 | 2016 | 483 | 0.030 |
Why?
|
Cardiac Catheterization | 1 | 2017 | 303 | 0.030 |
Why?
|
Artifacts | 1 | 2016 | 247 | 0.030 |
Why?
|
Causality | 1 | 2015 | 80 | 0.030 |
Why?
|
Kidney | 1 | 2020 | 1147 | 0.030 |
Why?
|
Registries | 1 | 2019 | 789 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 605 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2016 | 1074 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2013 | 303 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2018 | 2884 | 0.030 |
Why?
|
Safety-Based Medical Device Withdrawals | 1 | 2012 | 1 | 0.030 |
Why?
|
Cineradiography | 1 | 2012 | 25 | 0.030 |
Why?
|
Thrombosis | 1 | 2015 | 302 | 0.030 |
Why?
|
Atropine | 1 | 2012 | 60 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2015 | 1217 | 0.030 |
Why?
|
Endocardium | 1 | 2012 | 98 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2012 | 298 | 0.020 |
Why?
|
Comorbidity | 1 | 2015 | 951 | 0.020 |
Why?
|
Ultrasonography | 1 | 2013 | 712 | 0.020 |
Why?
|
Rats, Inbred WKY | 1 | 2010 | 32 | 0.020 |
Why?
|
Survival Rate | 1 | 2015 | 1903 | 0.020 |
Why?
|
Device Removal | 1 | 2012 | 168 | 0.020 |
Why?
|
Odds Ratio | 1 | 2012 | 683 | 0.020 |
Why?
|
Coloring Agents | 1 | 2010 | 65 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 900 | 0.020 |
Why?
|
Ultrasonic Therapy | 1 | 2010 | 36 | 0.020 |
Why?
|
Cohort Studies | 1 | 2017 | 2880 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 988 | 0.020 |
Why?
|
Reaction Time | 1 | 2010 | 310 | 0.020 |
Why?
|
Risk Assessment | 1 | 2017 | 2306 | 0.020 |
Why?
|
Membrane Potentials | 1 | 2010 | 436 | 0.020 |
Why?
|
Swine | 1 | 2010 | 587 | 0.020 |
Why?
|
Logistic Models | 1 | 2012 | 1214 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2014 | 2763 | 0.020 |
Why?
|
Kinetics | 1 | 2010 | 1530 | 0.020 |
Why?
|
Aconitine | 1 | 2007 | 4 | 0.020 |
Why?
|
Atrial Function, Right | 1 | 2007 | 13 | 0.020 |
Why?
|
Cholinergic Fibers | 1 | 2007 | 24 | 0.020 |
Why?
|
Fourier Analysis | 1 | 2007 | 128 | 0.020 |
Why?
|
Electrophysiology | 1 | 2007 | 403 | 0.020 |
Why?
|
Disease Progression | 1 | 2010 | 1492 | 0.020 |
Why?
|
Age Factors | 1 | 2010 | 1873 | 0.020 |
Why?
|
Aging | 1 | 2010 | 720 | 0.020 |
Why?
|